Donald Francis Selected Research

Immunoglobulin G (IgG)

1/2017	V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.
3/2014	Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.
1/2013	Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Donald Francis Research Topics

Disease

7	Infections 01/2017 - 08/2012
2	HIV Infections (HIV Infection) 03/2014 - 07/2012
1	Disease Progression 04/2013
1	Acquired Immunodeficiency Syndrome (AIDS) 11/2007

Drug/Important Bio-Agent (IBA)

5	VaccinesIBA 03/2014 - 11/2007
4	AIDSVAXIBA 03/2014 - 07/2012
4	AIDSVAX B-EIBA 03/2014 - 07/2012
3	Immunoglobulin A (IgA)IBA 01/2017 - 01/2013
3	Immunoglobulin G (IgG)IBA 01/2017 - 01/2013
3	AntibodiesIBA 12/2016 - 01/2013
1	Complement System Proteins (Complement)IBA 01/2017
1	Neutralizing AntibodiesIBA 01/2013
1	EpitopesIBA 01/2013
1	Proteins (Proteins, Gene)FDA Link 08/2012
1	AIDS VaccinesIBA 07/2012
1	erdosteineIBA 07/2012